Hepatitis

FDA Announces Orphan Drug Designation for HDV Drug

FDA Announces Orphan Drug Designation for HDV Drug

By

The Orphan Drug Designation Program offers orphan status to biologics and drugs that are safe and effective for rare diseases; also for prevention use.

HCC Risk After HCV Direct-Acting Antiviral Treatment

HCC Risk After HCV Direct-Acting Antiviral Treatment

By

The occurrence or recurrence risk for hepatocellular carcinoma is unclear after direct-acting antiviral agents and interferon based therapy.

Three-Part Strategy Announced for Hepatitis A Outbreak

Three-Part Strategy Announced for Hepatitis A Outbreak

By

A 3-part strategy was announced to combat the hepatitis A outbreak in San Diego, California.

Update on Pediatric HCV: Screening, Treatment, and Other Considerations

Update on Pediatric HCV: Screening, Treatment, and Other Considerations

By

Experts discuss screening, treatment, and other considerations in pediatric HCV.

DAAs Effective for HCV in Patients With Thalassemia

DAAs Effective for HCV in Patients With Thalassemia

By

Researchers compared the safety and efficacy of sofosbuvir plus ledipasvir vs pegylated interferon and ribavirin for 12 weeks in patients with thalassemia major and hepatitis C virus genotype 1 or 4.

Hepatitis B, Hepatitis C, HIV More Common in Severe Mental Illness

Hepatitis B, Hepatitis C, HIV More Common in Severe Mental Illness

By

HIV, hepatitis B, and hepatitis C infections are more prevalent among patients with severe mental illness than in the general population.

CDC: More Interventions Needed to Aid HCV Elimination Program in Country of Georgia

CDC: More Interventions Needed to Aid HCV Elimination Program in Country of Georgia

More interventions are needed to meet the target of hepatitis C virus elimination in the country of Georgia, defined as a 90% reduction in prevalence by 2020.

AAP: Hepatitis B Vaccine Should Be Given Within 24 Hours of Birth

AAP: Hepatitis B Vaccine Should Be Given Within 24 Hours of Birth

The first dose of the hepatitis B vaccine should be given within the first 24 hours of life.

 HCV Treatment Administered by Non-Specialists Safe, Effective

HCV Treatment Administered by Non-Specialists Safe, Effective

Non-specialists, including primary care providers and nurse practitioners, safely and effectively administer direct-acting antiviral therapy for hepatitis C virus to patients seen in FQHCs.

Hepatitis B: Search for the Cure and Challenges That Remain

Hepatitis B: Search for the Cure and Challenges That Remain

By

One of the main challenges in managing and controlling hepatitis B infection today is identifying people who are infected and ensuring that they have access to suitable treatment.

FDA Expands Epclusa® Indication for HCV/HIV Co-infection

FDA Expands Epclusa® Indication for HCV/HIV Co-infection

By

The FDA has approved an expanded indication for Epclusa to include the use of this once-daily single tablet regimen in patients co-infected with chronic hepatitis C virus and HIV.

New WHO Guidelines for Hepatitis B Virus Vaccine

New WHO Guidelines for Hepatitis B Virus Vaccine

By

The World Health Organization published a position paper with updated recommendations on the use of the hepatitis B vaccine regarding target groups, immunization schedules, and storage and distribution.

Hepatitis C Virus Infection and Cardiovascular Disease Risk

Hepatitis C Virus Infection and Cardiovascular Disease Risk

By

Epidemiological data demonstrate a link between HCV infection and cardiovascular disease, whereas treatment studies suggest viral eradication may lower the risk for cardiovascular morbidity and mortality.

Steatosis: An Independent Risk Factor for Fibrosis in Chronic HCV

Steatosis: An Independent Risk Factor for Fibrosis in Chronic HCV

By

Steatosis, hypertension, older age, obesity, and HIV are risk factors for liver fibrosis in African-Americans with chronic hepatitis C.

Improving Hepatitis C Screening With EHR-Based Prompts

Improving Hepatitis C Screening With EHR-Based Prompts

Using an electronic health record-based can improve HCV screening rates among baby boomers.

FDA Approves Pan-Genotypic Treatment for HCV

FDA Approves Pan-Genotypic Treatment for HCV

By

FDA has approved Mavyret (glecaprevir and pibrentasvir) for the treatment of adults with chronic hepatitis C virus.

New Treatment Options for Rheumatic Manifestations of HCV

New Treatment Options for Rheumatic Manifestations of HCV

By

Patients with HCV are at risk for several extrahepatic sequelae. Find out what they are and the new treatment options for managing HCV in patients with rheumatic symptoms.

Ledipasvir-Sofosbuvir Plus Ribavirin Offers Alternative in GT3 HCV

Ledipasvir-Sofosbuvir Plus Ribavirin Offers Alternative in GT3 HCV

By

Fixed-dose ledipasvir-sofosbuvir plus weight-based ribavirin may offer a treatment alternative in treatment-naïve patients with non-cirrhotic GT3 HCV.

Subcirrhotic Liver Stiffness Cuts HCC Risk in Hepatitis B

Subcirrhotic Liver Stiffness Cuts HCC Risk in Hepatitis B

For patients with chronic hepatitis B, achievement of subcirrhotic range of liver stiffness with antiviral therapy is linked to lower risk of hepatocellular carcinoma.

Immunoassay Uses Oral Fluid to Assess Hepatitis E Infection

Immunoassay Uses Oral Fluid to Assess Hepatitis E Infection

A noninvasive oral fluid-based immunoassay has high sensitivity and specificity for identifying recent and past hepatitis E virus.

FDA Approves Single-Tablet HCV Regimen

FDA Approves Single-Tablet HCV Regimen

By

The FDA approved Vosevi for the retreatment of adults with chronic hepatitis C virus genotypes 1-6.

Telbivudine During Early Pregnancy Prevents HBV Transmission

Telbivudine During Early Pregnancy Prevents HBV Transmission

By

A study showed that telbivudine administered during early and middle pregnancy prevented transmission of hepatitis B virus infection from mother to infants in all participants receiving antiviral treatment.

DAA-Based Eradication of HCV Associated With Improved Glycemic Control

DAA-Based Eradication of HCV Associated With Improved Glycemic Control

Direct-acting antiviral treatment of hepatitis C virus improved glycemic control for patients with type 2 diabetes.

Entecavir/Tenofovir Tx for Chronic HBV Beyond 5 Years Decreases HCC Rate

Entecavir/Tenofovir Tx for Chronic HBV Beyond 5 Years Decreases HCC Rate

Hepatocellular carcinoma decreases beyond year 5 of entecavir/tenofovir therapy in Caucasian patients with chronic hepatitis B virus.

Point-of-Care Test for Active Hepatitis C Virus Infection

Point-of-Care Test for Active Hepatitis C Virus Infection

By

Point-of-care test was found to have high sensitivity and specificity for detecting HCV RNA in both capillary whole-blood samples collected by finger stick and in plasma samples collected by venipuncture.

Management of HCV in Liver Transplant Candidates and Recipients

Management of HCV in Liver Transplant Candidates and Recipients

By

Expert insight from Leslie B. Lilly, MD, FRCPC, medical director of GI Transplantation from the Toronto General Hospital in Canada, about direct-acting antivirals in the management of hepatitis C virus in the liver transplantation setting.

EASL Raises Serious Concerns Over Cochrane Review of DAAs for HCV

EASL Raises Serious Concerns Over Cochrane Review of DAAs for HCV

By

The European Association for the Study of the Liver raises concerns over Cochrane Review of direct acting antivirals for hepatitis C virus.

HCV Cure Rates High in HIV Coinfection With Integrated Healthcare Program

HCV Cure Rates High in HIV Coinfection With Integrated Healthcare Program

For patients with HCV and HIV coinfection, treatment is effective with standardized nurse/pharmacist support at urban clinics.

Screening for Viral Hepatitis Recommended Before Biologics in RA

Screening for Viral Hepatitis Recommended Before Biologics in RA

By

The Turkish Society of Rheumatology proposed a guideline of hepatitis screening in patients with rheumatoid arthritis.

Liver Cancer Mortality Rates Have Doubled Since Mid-1980s

Liver Cancer Mortality Rates Have Doubled Since Mid-1980s

Liver cancer has become the fastest growing cause of cancer deaths in the Unites States.

Sign Up for Free e-newsletters